NASDAQ:DNTH Dianthus Therapeutics Q3 2026 Earnings Date & Estimates $82.37 -0.06 (-0.07%) Closing price 04:00 PM EasternExtended Trading$82.34 -0.03 (-0.03%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Dianthus Therapeutics is expected to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for November 4, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeAfter Market ClosesConference Call DateNovember 4, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Dianthus Therapeutics in Q3 2026Dianthus Therapeutics is expected to post earnings of -$0.9434 per share on revenue of $0.44 million. In the same quarter a year earlier Dianthus Therapeutics reported -$0.97 per share on revenue of $0.40 million. Dianthus Therapeutics last reported on August 4, 2026, posting -$0.90 per share and missing the -$0.8463 consensus estimate. Dianthus Therapeutics has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.9434Expected Revenue$0.44 millionPrior-Year EPS-$0.97Prior-Year Revenue$0.40 millionExpected Revenue Growth+12.1%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.90 (Missed by -$0.0537)Last Quarter Revenue$0.76 millionEPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Dianthus Therapeutics Q3 2026 Earnings FAQ When does Dianthus Therapeutics report Q3 2026 earnings? Dianthus Therapeutics (NASDAQ:DNTH) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Dianthus Therapeutics' Q3 2026 earnings call? Dianthus Therapeutics' Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Dianthus Therapeutics? Analysts expect Dianthus Therapeutics to post earnings of -$0.9434 per share for Q3 2026. How much revenue is Dianthus Therapeutics expected to report? The consensus revenue estimate for Dianthus Therapeutics is $0.44 million for Q3 2026. Dianthus Therapeutics Earnings HeadlinesDianthus Therapeutics, Inc. (NASDAQ:DNTH) Stock Rated "Moderate Buy" by Wall Street BrokeragesOctober 8 at 2:28 AM | americanbankingnews.comDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 1, 2026 | globenewswire.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.October 9 at 1:00 AM | Banyan Hill Publishing (Ad)Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual MeetingSeptember 29, 2026 | globenewswire.comDianthus Therapeutics (DNTH) Stock Looks Expensive After A 7x RunSeptember 24, 2026 | uk.finance.yahoo.comCan Dianthus Therapeutics (DNTH) Stay Undervalued Following Its $500 Million Stock Offering?September 24, 2026 | finance.yahoo.comSee More Dianthus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Dianthus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dianthus Therapeutics and other key companies, straight to your email. Email Address About Dianthus TherapeuticsDianthus Therapeutics (NASDAQ:DNTH) is a clinical-stage biotechnology company focused on developing targeted antibody therapies for autoimmune diseases. The company’s approach centers on selectively modulating the complement system, an immune pathway involved in inflammation and tissue damage, with the goal of creating treatments that may offer potent disease control and convenient dosing. Dianthus’ lead investigational product is DNTH103, a fully human monoclonal antibody designed to selectively inhibit activated C1s, a key protein in the classical complement pathway. DNTH103 is engineered for extended activity and subcutaneous administration and is being evaluated in immune-mediated neuromuscular and neurological disorders, including generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. The company is also advancing additional complement-targeted programs for autoimmune diseases. Dianthus serves global markets through its clinical development activities and is headquartered in the United States. As a development-stage biotechnology company, its products remain investigational and are subject to clinical testing and regulatory review before they may become commercially available.View Dianthus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
